Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ismigen for Nasal MRSA in Children with Allergic Rhinitis
NCT04637425Phase 3Completed
- Sponsor
- Medical University of Lublin
- Start
- Apr 2018
- Primary completion
- Aug 2020
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing Ismigen with Placebo (2 arms). Primary endpoint: Change in the growth intensity of the nasal Staphylococcus aureus colony at 3 months. Started Apr 2018; status: completed.
02
Drugs
polyvalent mechanical bacterial lysate
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04637425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637425.